Who are Permethrin 5%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elimite, Permethrin Cream, Permethrin Cream, 5%, Permethrin 1% rinse, Elimite™ Cream (permethrin) 5%, Permethrin 1%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/permethrin-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Permethrin 5% — Competitive Intelligence Brief

Permethrin 5% (Permethrin 5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pyrethroid [EPC].

marketed Pyrethroid [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

Permethrin 5% (Permethrin 5%) — Barzilai Medical Center.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Permethrin 5% TARGET	Permethrin 5%	Barzilai Medical Center	marketed	Pyrethroid [EPC]
Elimite	PERMETHRIN		marketed	Pyrethroid [EPC]		1986-01-01
Permethrin Cream	Permethrin Cream	University of Oxford	marketed	Pyrethroid [EPC]
Permethrin Cream, 5%	Permethrin Cream, 5%	Mayne Pharma International Pty Ltd	marketed	Synthetic pyrethroid insecticide	Voltage-gated sodium channels (arthropod nervous system)
Permethrin 1% rinse	Permethrin 1% rinse	Sun Pharmaceutical Industries, Inc.	phase 3	pyrethroid
Elimite™ Cream (permethrin) 5%	Elimite™ Cream (permethrin) 5%	Encube Ethicals Pvt. Ltd.	phase 3	Pyrethroid insecticide	Voltage-gated sodium channels
Permethrin 1%	Permethrin 1%	ParaPRO LLC	phase 3	pyrethroid	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pyrethroid [EPC] class)

· 1 drug in this class
Barzilai Medical Center · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Permethrin 5% — Competitive Intelligence Brief. https://druglandscape.com/ci/permethrin-5. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab